Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

NCT04134884 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Triple Negative Breast Cancer
Hormone Receptor Positive Tumor

Interventions

DRUG: Talazoparib
DRUG: ASTX727

Sponsor

Kathy Miller

Collaborators

[object Object]
[object Object]
[object Object]